ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

brensocatib

Also written as “Brensocatib”, “Brensocatib 10 mg” and “Brensocatib 25 mg”.

Its studies are mostly in Bronchiectasis · Nasal Polyps · Hidradenitis Suppurativa · Cystic Fibrosis · Renal Insufficiency, led by 2 companies.

Drug pageBrensocatib: every studyAll 17 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Oct 14, 202017 company-led studies, 1 open or runningNext primary completion: Nov 25, 2026 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Insmedits history only151 open or runningphase 3since Oct 14, 2020Jul 11, 2017Nov 25, 2026phase 1 · NCT07859007
AstraZeneca20 open or runningphase 1since Nov 3, 2014Nov 3, 2014none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of AstraZeneca only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Nov 3, 2014First study: phase 1 study in Safety, Pharmacokinetics, Pharmacodynamics, Food EffectFirst studyNCT02303574 · 89 enrolled · United Kingdom
  2. Jan 11, 2016Phase 1 study in Healthy SubjectsNCT02653872 · 15 enrolled · United Kingdom
  3. Jun 9, 2019Named brensocatibINNProposed as its International Nonproprietary Name in WHO's List 121

TargetBeta

CTSC →read by rule
“An orally bioavailable, small molecule, reversible inhibitor of dipeptidyl peptidase 1 (DPP1), ”NCIt, by rule
“Dipeptidyl peptidase I inhibitor”ChEMBL 37, by rule

Other programs on CTSC

ProgramCompanyFurthest phaseStudies
verducatibBoehringer Ingelheimphase 321
RSS0343Jiangsu HengRui Medicinephase 25

Studies

All 2 AstraZeneca leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT02653872Healthy Subjects · United Kingdom1CompletedApr 13, 201615
NCT02303574Safety, Pharmacokinetics, Pharmacodynamics, Food Effect · United Kingdom1CompletedAug 3, 201689

How it is read

Names in the registry

  • “Brensocatib”, 10 entries
  • “Brensocatib 10 mg”, 2 entries
  • “Brensocatib 25 mg”, 2 entries
  • “Brensocatib Oral Solution”, 1 entry
  • “Brensocatib Oral Tablet”, 1 entry

Codes read as this program: AZD7986.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.